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NIEHS and National Toxicology Program
(NTP) researchers recently shared with the
public their research on transgenic mouse
models aimed at evaluating how they can be
used fortesting the carcinogenicity ofchemi-
cals and drugs. Research suggests that some
ofthese models have thepotential to identify
carcinogens more quickly and at a fraction
ofthe cost ofthe standard two-year rodent
bioassayforcarcinogenicitytesting.
Promising research on three specific
transgenic mouse models prompted a meet-
ing of the NTP's Board of Scientific
Counselors (BSC) at the NIEHS on 5-6
February 1998. The purpose ofthe meeting
was to review the NTP/NIEHS efforts to
evaluate these models and to discuss incor-
porating these models into the current
chemical testing framework. The meeting,
which was open to the public, was heavily
attended bygovernment and industry repre-
sentatives.
"This meeting was a milestone in the
development of alternative methods," says
Raymond Tennant, chief of the NIEHS
LaboratoryofEnvironmental Carcinogenesis
and Mutagenesis (LECM). "It was a forum
in which new data were available from NTP
that could bejudged for their scientific value
andpotential utility to theNTP."
Tennant discusses the rationale for using
transgenic models, saying, "By targeting the
chemical effects to genes known to play a
role in tumor development, we can mini-
mize some ofthe factors that complicate the
bioassay results by shortening the duration
of the experiment, minimizing strain- and
species-specific complications and providing
mechanistic insight into the action of the
chemicals."
NIEHS researchers presented new find-
ings on the p53defand Tg.AC transgenic
models, and researchers from Japan who
have been collaborating with NIEHS scien-
tists presented new research on the rasH2
model.
The p53deftransgenic model possesses
only one functional copy ofthe p53 tumor
suppressor gene, which suppresses cancer in
humans and rodents and is critical to the
recognition and repair of DNA damage.
Based on 26-week exposures, researchers
have found that this model identifies
transspecies mutagenic carcinogens, which
are ofthe greatest concern for human health
risks, says John French, group leader in
transgenic carcinogenesis in the LECM.
French presented newmechanistic datafrom
studies with the model that showed that loss
ofthe wild-typep53 allele is associated with
rapid induction ofcancer.
The TgAC mouse model was produced
by pronudear injection ofa v-Ha-ras gene,
which alters signal 0-
transduction and
growth control. The
inductionofthis onco-
gene, which is present
in all tissues of this
mouse line, results in
enhancedsusceptibility
to the development of
tumors in response to
physical wounding, or
to mutagenic or non-
mutagenic chemical
carcinogens on skin
and other tissues.
These models have
been evaluated using
chemicals varying A new breed of mouse
widely in their carcino- the p53tumor suppres< genicpotency and pre- germlinefunctional and
sumedmechanism.
The third model presented at the meet-
ing, the rasH2, was developed by Japanese
scientists at the Central Institute of
Experimental Animals in Kawasaki and the
National Institute of Health Sciences in
Tokyo. This model carries 56 copies ofthe
normal human H-ras gene, which is
involved in cell growth and differentiation.
The model has been found to work well in
identifying genotoxic carcinogens, says
Robert Maronpot, chiefoftheLaboratory of
Experimental Pathology at the NIEHS.
Researchers have found that exposures to
genotoxic carcinogens result in mutations of
the normal H-ras gene. Studies to evaluate
the model's ability to identify other types of
carcinogens are ongoing, Maronpot says,
and the NIEHS will continue to collaborate
withJapaneseresearchers on this model.
Representatives fromthe Food and Drug
Administration (FDA) and the EPA also
offered theiragencies' perspectives on the use
of transgenic models. The FDA is "fairly
open" about accepting alternative models for
carcinogenicity studies on pharmaceuticals,
says Joseph Contrera, associate director for
regulatory research in the FDA's Office of
Testing and Research. As ofearly 1997, the
FDA will consider any scientifically justified
alternative model that a sponsor may pro-
pose as an alternative to one of the two
required two-year rodent assays for pharma-
ceuticals. "We're trying to stimulate people
to develop and invest in some new
approaches and supply new insight into risk
assessment," Contrerasays.
Speaking at the meeting, Vicki Dellarco,
senior geneticist in the EPA's Office of
Water, said there is a range ofpossibilities of
how transgenic models could be utilized by
the EPA, from setting research priorities to
hazard ranking. Specifically, Dellarco said
these shorter-term transgenic models could
model. The p53defmouse model has only one copy of
sor gene. The graphic overlay above compares the
inactivated p53alleles.
have an important role in testing a number
ofpollutants that are required to be evaluat-
ed under the Safe Drinking Water Act, pos-
siblysaving time and money.
BSC members were asked to address
four questions raised by the NTP: is the
NTP approach to evaluation and validation
oftransgenic models for use in cancer bioas-
says sufficient and appropriate; are the scien-
tific needs ofregulatory agencies being ade-
quately addressed; how can existing models
be best utilized (including consideration of
their limitations); and what new models are
needed (i.e., should the NTP seek to develop
organ-specific tumor models).
A formal report from the board address-
ing these questions was recently submitted
to the NTP, and will serve as a guide in
developing future studies, says George
Lucier, director of the Environmental
Toxicology Program at the NIEHS. Overall,
the board reacted positively to the NTP
studies, saying that it is appropriate for the
NTP and the NIEHS to assume aleadership
role in transgenic model research, Lucier
says.
The NIEHS is currently collaborating
with other research groups as part of an
international effort spearheaded by the
International Life Sciences Institute, a non-
profit scientific organization in Washington,
DC. The effort is working to test more
chemicals as well as a variety of alternative
models, says Maronpot. Meanwhile, he says,
NIEHS and NTP researchers will continue
to investigate transgenic models, looking at
specific applications such as important target
tissue sites in human cancer and
dose-response, as well as other routes of
exposure such as inhalation.
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